Clinical trials: Hepatitis B, Chronic
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04059198
- Testing
- Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF)
- Where
- 2 sites in Hong Kong
- Volunteers
- 5 people
- Sponsor
- F-star Therapeutics, Inc.
Hepatitis B
Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)
This is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB.
- Trial name
- TDF in CHB (NCT01300234)
- Testing
- Tenofovir disoproxil fumarate (TDF) tablets, Adefovir dipivoxil (ADV) tablets
- Where
- 20 sites in China
- Volunteers
- 512 people
- Sponsor
- GlaxoSmithKline
Liver Fibrosis Due to Chronic Hepatitis B Infection
A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
The overall goal of this trial is to evaluate the efficacy of FG-3019 for reversing liver fibrosis in subjects with chronic hepatitis B infection who are beginning antiviral therapy with entecavir.
- Trial name
- NCT01217632
- Testing
- FG-3019, Entecavir
- Where
- 9 sites in Hong Kong, Thailand
- Volunteers
- 114 people
- Sponsor
- Kyntra Bio
Chronic HBV Infection
Study of LW231 in Participants With Chronic Hepatitis B
This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B…
- Trial name
- NCT07179575
- Testing
- LW231
- Where
- 2 sites in China
- Volunteers
- 270 people
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Hepatitis B, Chronic
A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
In this open-label multicenter study the long-term effect of Pegasys monotherapy on pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis B.
- Trial name
- NCT00962975
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 6 sites in United States, New Zealand and 2 more
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
- Trial name
- NCT04684914
- Testing
- HepTcell
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Altimmune, Inc.
Chronic Hepatitis B Infection
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment…
- Trial name
- NCT07342881
- Testing
- Pevifoscorvir Sodium (ALG-000184)
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Liver Fibrosis
ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B
This study will evaluate how liver stiffness measurements made with ShearWave™ Elastography (SWE) correspond with a biopsy result (currently the gold standard).
- Trial name
- NCT02313649
- Where
- 15 sites in China
- Volunteers
- 447 people
- Sponsor
- SuperSonic Imagine
Chronic Hepatitis B
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied.
- Trial name
- NCT04846491
- Testing
- Peginterferon alfa-2b injection, TDF
- Where
- 33 sites in China
- Volunteers
- 475 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hep B, Chronic Hepatitis b
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.
- Conditions
- Chronic Hep B, Chronic Hepatitis b, Chronic Hepatitis, HBV
- Trial name
- NCT06671093
- Testing
- Tune-401
- Where
- 3 sites in Hong Kong, Moldova and 1 more
- Volunteers
- 36 people
- Sponsor
- Tune Therapeutics, Inc.
Chronic Hepatitis B
Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently…
- Trial name
- NCT00307489
- Testing
- tenofovir DF, emtricitabine /tenofovir DF
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional…
- Trial name
- NCT04465916
- Testing
- EYP001a, Nucleotide analogue (Entecavir or Tenofovir Disoproxil)
- Where
- 18 sites in Australia, Hong Kong and 2 more
- Volunteers
- 26 people
- Sponsor
- Enyo Pharma
Chronic Hepatitis B
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B
An open study to Evaluate the Efficacy, Safety and Sustained effect of Clevudine monotherapy or Adefovir and Clevudine combination in proportion to Roadmap concept in Patients with chronic hepatitis B.
- Trial name
- NCT01264133
- Testing
- Clevudine, Adefovir
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis B
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
Provide adefovir dipivoxil (Hepsera) 10 mg once daily to patients with chronic hepatitis B virus (HBV) infection who have completed a Gilead-sponsored study of adefovir dipivoxil and require continued access to adefovir dipivoxil.
- Trial name
- NCT00158704
- Testing
- Hepsera
- Volunteers
- 400 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B, HBV (Hepatitis B Virus)
Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
This study is an open-label, 2-Part (Single Ascending Dose [Part 1] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB).
- Trial name
- NCT06661148
- Testing
- EPI-003
- Where
- 4 sites in Australia, China and 1 more
- Volunteers
- 36 people
- Sponsor
- Epigenic Therapeutics, Inc
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07897448
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
Hepatitis B, Chronic
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Trial name
- MARCH (NCT04856085)
- Testing
- VIR-2218, VIR-3434, PEG-IFNα
- Where
- 37 sites in United States, Canada and 10 more
- Volunteers
- 244 people
- Sponsor
- Vir Biotechnology, Inc.
Infectious Disease
Phase 2, Multiple Ascending Dose Proof of Concept Study
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
- Trial name
- NCT02710604
- Testing
- CMX157, TDF
- Where
- Thailand
- Volunteers
- 62 people
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Chronic Hepatitis B, Hepatitis B, Chronic
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as…
- Trial name
- NCT05630807
- Testing
- Bepirovirsen
- Where
- 177 sites in United States, Argentina and 24 more
- Volunteers
- 981 people
- Sponsor
- GlaxoSmithKline
Chronic HBV Infection
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.
- Trial name
- NCT04470388
- Testing
- EDP-514
- Where
- 10 sites in Hong Kong, Taiwan
- Volunteers
- 25 people
- Sponsor
- Enanta Pharmaceuticals, Inc